Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today reported that the Company has received an order for 66 QS-B220 explosives trace detection systems in Norway. The systems, many of which have already been shipped, are scheduled to be deployed for passenger and baggage screening in an airport environment.
"We estimate that the near-term market for new trace detection screening programs in aviation security in Europe will exceed $45 million. Implant Sciences' leadership in non-radioactive ion mobility spectrometry technology has been demonstrated in passing the ECAC Common Evaluation Protocol on the first try, as well as in numerous airport trials. We believe our field-proven reliability and low false alarm rates will lead to even more airports selecting Implant Sciences as their preferred ETD vendor," stated Dr. Darryl Jones, Implant Sciences' Vice President of Global Sales and Marketing.
"One of the primary requirements of this customer was the quick delivery and installation of non-radioactive ETD systems across the vast distances and challenging terrain covered by these airports. Implant Sciences' investment in manufacturing capability made it possible for us to exceed the customer's expectations in this area," added Richard Nelson, Implant Sciences' General Manager, EMEA.
Key data points: The market size in 2031 = $6.9 billion, growth forecast = 3.8% annually for the next 7 years. Scroll below to get more insights. This market report covers trends, opportunities, and forecasts in the global flight inspection market to 2031 by solution (service and system), end use (commercial airports, defense airports, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)
Download free sample pagesAbout the QS-B220 Desktop Explosives and Drugs Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as illicit drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
